Evidence map›Paper›PMID 38612447›Full record

ArticleInternational journal of molecular sciences2024

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A.

Rou Xiao, Yan Chen, Zhiqing Hu, Qiyu Tang, Peiyun Wang, Miaojin Zhou, Lingqian Wu, Desheng Liang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rou XiaoCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.ORCID 0000-0003-1929-0784
Yan ChenCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Zhiqing HuCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Qiyu TangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Peiyun WangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Miaojin ZhouCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.ORCID 0000-0002-6636-6000
Lingqian WuCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Desheng LiangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.ORCID 0000-0002-9451-8585
Central South University · CN

Funding

the National Key Research and Development Program of Chin 2022YFC2703700the National Key Research and Development Program of China 2022YFC2703400the National Natural Science Foundation of China 82101957the National Natural Science Foundation of China 82271752
6 · The paper itself

Abstract

Hemophilia A (HA) is a common X-linked recessive hereditary bleeding disorder. Coagulation factor VIII (FVIII) is insufficient in patients with HA due to the mutations in the

Indexed as

Hemophilia AHemostaticsEnhancer Elements, GeneticFactor VIIIGenetic TherapyHumansFactor VIIIHemostaticscell therapyFVIII-Padua enhancer C400gene therapyHemophilia Auniversal targeted gene modification

Identifiers

PMID38612447
PMCPMC11011560
OpenAlexW4393149504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.